Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.

Tumor recurrence and metastasis remain the major obstacles for the successful treatment of patients diagnosed with prostate cancer (PCa). In recent years, long non-coding RNAs (lncRNAs) have been considered as key regulators of tumor behavior. In this study, we investigated the biological role and clinical relevance of the lncRNA LOC400891 in prostate cancer. Using of lncRNAs expression chips screening and the biological analysis, we found the target lncRNA (LOC400891). Moreover, the expression levels of lncRNA LOC400891 in PCa tissues and cell lines were evaluated by quantitative real-time PCR (qRT-PCR), and its association with biochemical recurrence-free survival of patients was analyzed by statistical analysis. Furthermore, the effect of LOC400891 on proliferation, migration, and invasion was studied in PCa cells. We found that the expression level of LOC400891 was higher in PCa tissues and cells compared to adjacent non-tumor tissues and normal prostate stromal immortalized cells WPMY-1. The patients with higher LOC400891 expression had an advanced clinical features and a shorter biochemical recurrence-free survival time than those with lower LOC400891 expression. Furthermore, multivariate analysis showed that the status of LOC400891 expression was an independent predictor of biochemical recurrence-free survival in PCa. We also found that knockdown of LOC400891 could inhibit cell proliferation, migration, and invasion in vitro study. Our data suggested that lncRNA LOC400891 was a novel molecule involved in PCa progression, which provided a potential prognostic biomarker and therapeutic target.